Wednesday, April 29, 2020

Glenmark Pharma gets DCGI nod for clinical trials of Favipiravir tablets on COVID-19 patients

Glenmark Pharma gets DCGI nod for clinical trials of Favipiravir tablets on COVID-19 patients Having internally developed the active pharmaceutical ingredients (API) and the formulations for the product, the company filed the product for clinical trials with the DCGI and has received approval for conducting the trial on mild to moderate patients, Glenmark Pharmaceuticals said in a statement.

from Moneycontrol Business News https://ift.tt/2zJWe9B
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

S&P 500, Nasdaq end higher on Amazon-OpenAI deal; Fed path forward grows murky

Artificial intelligence deals propelled the S&P 500 and Nasdaq higher on Monday, with Amazon's $38 billion agreement with OpenAI and...